KUALA LUMPUR, March 8 — Novartis Malaysia has announced the availability of Sybrava, an effective and sustained treatment to control low-density lipoprotein cholesterol (LDL-C).
Sybrava is an innovative therapy that aids in lowering LDL-C levels in the blood as an add-on to existing cholesterol-lowering treatments and lifestyle modifications.
This therapy provides effective and sustained LDL-C reduction, improving patients’ health with only two maintenance doses a year.
Based on the results of ORION 10, a clinical study, the therapy provides an effective LDL-reduction of up to 52 per cent in patients with elevated LDL-C despite already being on maximally tolerated cholesterol-lowering treatment.
“Sybrava helps medical professionals treat individuals who have high cholesterol despite treatment with maximally tolerated statins,” said Elwakil Mohamed, country president for Novartis Malaysia.
“It offers a combination of a convenient twice-a-year maintenance dosing schedule, as well as the ability to be used in primary care and provide sustained reductions in LDL-C is a hugely positive milestone in patient care.
“We at Novartis Malaysia are committed to treating hypercholesteremia — or a high blood cholesterol level — with new innovative therapies,” he added.
